Summary of COVID-19 SNS812 studies

1. Chang et al., Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: A Phase II Trial

90 patient SNS812 early treatment RCT: 17% improved viral clearance (p=0.02).
RCT 135 patients with mild to moderate COVID-19 showing significant efficacy of aerosolized siRNA SNS812 in reducing viral load and accelerating symptom resolution. The trial randomized patients to 200mg, 100mg, or placebo arms, with treatment initiated within 3 days of symptom onset. The 200mg group demonstrated significantly faster viral clearance and greater viral load reduction starting from day 1. Symptom improvement showed dose-dependent effects with significant reduction in time to resolution for 6 of 14 symptoms, including shortness of breath and loss of taste/smell. Authors do not provide enough information on symptomatic outcomes for meta analysis. The siRNA targets a highly conserved region of the viral RNA-dependent RNA polymerase gene and showed efficacy against multiple Omicron variants.
Mar 2025, CROI 2025, https://www.croiconference.org/wp-content/uploads/sites/2/posters/2025/158-2025.pdf, https://c19p.org/chang10